title: NAD(+) supplementation as a novel approach to cURIng HCC?
abstract: In this issue of Cancer Cell, Tummala and colleagues demonstrate that unconventional prefoldin RPB5 interactor (URI) expression in hepatocytes leads to hepatocellular carcinoma (HCC) development by interacting with L-tryptophan/kynurenine/nicotinamide adenine dinucleotide (NAD(+)) metabolism. The results suggest that supplementation of NAD(+) may be a prophylactic or therapeutic approach in HCC.
authors.affiliation: Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany.
authors.forename: Ingmar
authors.initials: I
authors.lastname: Mederacke
authors.affiliation: Department of Medicine, Columbia University, College of Physicians & Surgeons, 1150 St. Nicolas Avenue, New York, NY 10032, USA; Institute of Human Nutrition, Columbia University, College of Physicians & Surgeons, 1150 St. Nicolas Avenue, New York, NY 10032, USA. Electronic address: rfs2102@cumc.columbia.edu.
authors.forename: Robert F
authors.initials: RF
authors.lastname: Schwabe
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D004249:DNA Damage; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008113:Liver Neoplasms / Q000473:pathology*; D009243:NAD / Q000378:metabolism*; D012097:Repressor Proteins / Q000378:metabolism*
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; D012097:Repressor Proteins; C117184:URI1 protein, human; C485517:Uri1 protein, mouse; D009243:NAD